Powering the Immune System to Transform Lives
Our Pipeline
A Deep, Broad Pipeline to Address Unmet Patient Need
Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.
Hepatitis Delta
tobevibart1 + elebsiran
- Goal:
- Treatment
- Phase:
- Phase 3,33%
Learn more about our therapeutic focus on Hepatitis Delta
Solid Tumors
VIR-5818 (HER2)2 ± pembrolizumab
- Goal:
- Treatment
- Phase:
- Phase 1,75%
VIR-5500 (PSMA)2
- Goal:
- Treatment
- Phase:
- Phase 1,75%
VIR-5525 (EGFR)2
- Goal:
- Treatment
- Phase:
- Phase 1,25%
Undisclosed PRO-XTEN™ TCE targets3
- Goal:
- Treatment
- Phase:
- Pre-clinical,75%
Learn more about our therapeutic focus on Oncology
HIV Cure
Preclinical antibody candidates
- Collaborator:
- Gates Foundation
- Goal:
- Treatment
- Phase:
- Pre-clinical,75%
Learn more about our therapeutic focus on HIV
1 Tobevibart incorporates Xencor’s Xtend™ and other Fc technologies.
2 Masked TCEs licensed from Sanofi.
3 Vir Biotechnology has exclusive rights to the PRO-XTEN™ masking platform for oncology and infectious disease. PRO-XTEN™ is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
HER2: human epidermal growth factor receptor 2; PSMA: prostate-specific membrane antigen; EGFR: epidermal growth factor receptor; TCE: T-cell engager; HIV: human immunodeficiency virus.